PRTK News and Press, Paratek Pharmaceuticals Inc. From 08/09/21

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter -- Reported $37.9 Million in Revenue from the Delivery of the First BARDA Procurement of NUZYRA -- Received FDA Ap...

The stock of Paratek Pharmaceuticals has fallen since we last took an in-depth look at this antibiotic company in March. Most of this is due to weakness in the sector. The company continues to make solid progress, and its shares are far below analyst firm price targets. A ful...

Gainers: JD +4.7%. MVST +3.9%. MDRX +3.7%. MCFE +2.8%. ADVM +2.8%. Losers: ETON -12.9%. GDS -6.7%. PRTK -5.1%. PDD -3.0%. NAUT -1.7%. For further details see: MVST, MDRX, ETON and GDS among after hours movers

Score Media and Gaming (NASDAQ:SCR) +65% Penn National Gaming inks deal to acquire Score Media and Gaming Ensysce Biosciences (NASDAQ:ENSC) +38% announces notice of allowance from the U.S. Patent and trademark office for Patent entitled “compositions comprising enzyme-cl...

Acurx Pharmaceuticals Joins the Antimicrobials Working Group PR Newswire WASHINGTON , Aug. 5, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of c...

Paratek Pharmaceuticals (NASDAQ:PRTK) announces that the company’s novel, once-daily oral and intravenous antibiotic NUZYRA (omadacycline) has been added to the Center for Disease Control and Prevention’s (CDC) plague guidelines. Shares up more than 12% post marke...

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for civilian...

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...

BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, go...

Paratek Pharmaceuticals (PRTK) announced that it delivered the first procurement of NUZYRA valued at ~$38M to the Biomedical Advanced Research and Development Authority ((BARDA)).BARDA is part of the Office of the Assistant Secretary for Preparedness and Response ((ASPR)) at the U.S. Dep...